August 8, 2019 07:04 AM EDTUpdated 03:07 PM
Pharma
FDA+

CMS will now cov­er pricey CAR-T ther­a­pies for Medicare pa­tients

Natalie Grover

Reporter

The Cen­ters for Medicare and Med­ic­aid (CMS) has been busy. Ear­li­er this week, the agency pre­scribed ways to re­sus­ci­tate the fledg­ling an­tibi­ot­ic in­dus­try by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

A service from the Financial Times